GlassScriptPhysician profile
Danielle K Pou
NPI 1073839304
$5,497.96
in general payments reported to CMS, 2019-2025
46 companies · $53.90 in 2025
The $53.90 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,240 · 2023: $2,417 · 2024: $1,788 · 2025: $53.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,241 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,241.37 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $642.03 | 2022-2025 | |
| Pfizer INC. | $365.82 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $325.63 | 2022-2024 | Ingrezza, Ongentys |
| Lilly USA, LLC | $281.33 | 2022-2024 | Reyvow, Emgality, Amyvid |
| Novartis Pharmaceuticals Corporation | $281.03 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $241.71 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $235.55 | 2022-2024 | Ultomiris |
| Emd Serono, INC. | $232.95 | 2022-2024 | Mavenclad |
| Ucb, INC. | $227.49 | 2022-2024 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $192.11 | 2022-2024 | Xcopri |
| Eisai INC. | $184.40 | 2022-2024 | |
| Boston Scientific Corporation | $162.55 | 2022-2024 | |
| Harmony Biosciences LLC | $157.16 | 2022-2024 | Wakix |
| Argenx US, INC. | $156.76 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Merz Pharmaceuticals, LLC | $153.17 | 2022-2024 | Xeomin |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $147.74 | 2022-2023 | Ocrevus |
| Neurelis, INC. | $143.29 | 2023-2024 | Valtoco |
| Tanabe Pharma America, INC. | $126.54 | 2022-2024 | |
| Acorda Therapeutics, INC | $123.37 | 2022-2023 | Inbrija |
| Biohaven Pharmaceutical Holding Company LTD. | $113.48 | 2022 | |
| Octapharma USA, INC. | $91.98 | 2023 | Panzyga |
| Tg Therapeutics, INC. | $75.42 | 2023-2024 | |
| Biogen, INC. | $69.43 | 2023-2024 | Skyclarys, Vumerity, Tysabri |
| Abbott Laboratories | $65.44 | 2023 | Infinity |
| Amgen INC. | $61.00 | 2023 | Aimovig |
| Celgene Corporation | $56.40 | 2022-2023 | Zeposia |
| Lundbeck LLC | $54.06 | 2023-2024 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $53.61 | 2023 | Rytary |
| Kyowa Kirin, INC. | $47.96 | 2023-2024 | Nourianz |
| Acadia Pharmaceuticals INC | $46.44 | 2023-2024 | Nuplazid |
| Catalyst Pharmaceuticals, INC. | $38.29 | 2023-2024 | Fycompa |
| Otsuka America Pharmaceutical, INC. | $33.70 | 2023 | Rexulti, Nuedexta |
| Ani Pharmaceuticals, INC. | $27.97 | 2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $26.20 | 2023 | Uplizna |
| Livanova USA, INC. | $25.78 | 2022 | |
| Grt US Holding, INC. | $23.97 | 2022 | |
| Ge Healthcare | $23.01 | 2023 | |
| Collegium Pharmaceutical, INC. | $22.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.98 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.67 | 2022 | |
| Averitas Pharma INC. | $21.55 | 2024 | Qutenza |
| Genentech, INC. | $21.21 | 2024 | Ocrevus |
| Avion Pharmaceuticals | $20.64 | 2023 | Dhivy |
| Astrazeneca Pharmaceuticals LP | $18.26 | 2022 | |
| Banner Life Sciences, LLC | $18.23 | 2023 | |
| Genzyme Corporation | $17.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Pou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.